156 related articles for article (PubMed ID: 8438050)
21. Clinical, histological and molecular reversibility of zidovudine myopathy.
Masanés F; Barrientos A; Cebrián M; Pedrol E; Miró O; Casademont J; Grau JM
J Neurol Sci; 1998 Aug; 159(2):226-8. PubMed ID: 9741412
[TBL] [Abstract][Full Text] [Related]
22. AZT-induced mitochondrial myopathy.
Tomelleri G; Tonin P; Spadaro M; Tilia G; Orrico D; Barelli A; Bonetti B; Monaco S; Salviati A; Morocutti C
Ital J Neurol Sci; 1992 Dec; 13(9):723-8. PubMed ID: 1336487
[TBL] [Abstract][Full Text] [Related]
23. Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy.
Chariot P; Monnet I; Mouchet M; Rohr M; Lefaucheur JP; Dubreuil-Lemaire ML; Chousterman M; Gherardi R
Arthritis Rheum; 1994 Apr; 37(4):583-6. PubMed ID: 8147937
[TBL] [Abstract][Full Text] [Related]
24. Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage.
Masini A; Scotti C; Calligaro A; Cazzalini O; Stivala LA; Bianchi L; Giovannini F; Ceccarelli D; Muscatello U; Tomasi A; Vannini V
J Neurol Sci; 1999 Jul; 166(2):131-40. PubMed ID: 10475107
[TBL] [Abstract][Full Text] [Related]
25. Nuclear and mitochondrial changes of muscle fibers in AIDS after treatment with high doses of zidovudine.
Schröder JM; Bertram M; Schnabel R; Pfaff U
Acta Neuropathol; 1992; 85(1):39-47. PubMed ID: 1285495
[TBL] [Abstract][Full Text] [Related]
26. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
27. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished?
Simpson DM; Citak KA; Godfrey E; Godbold J; Wolfe DE
Neurology; 1993 May; 43(5):971-6. PubMed ID: 8492955
[TBL] [Abstract][Full Text] [Related]
28. [Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine].
Charton-Bain MC; Flamant M; Aubertin JM; Belair MF; Gilquin J; Kazatchkine M; Bruneval P
Gastroenterol Clin Biol; 1997; 21(12):979-81. PubMed ID: 9587562
[TBL] [Abstract][Full Text] [Related]
29. Muscle disease, HIV and zidovudine: the spectrum of muscle disease in HIV-infected individuals treated with zidovudine.
Manji H; Harrison MJ; Round JM; Jones DA; Connolly S; Fowler CJ; Williams I; Weller IV
J Neurol; 1993 Sep; 240(8):479-88. PubMed ID: 8263554
[TBL] [Abstract][Full Text] [Related]
30. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
31. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
32. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy.
Jeppesen TD; Schwartz M; Olsen DB; Wibrand F; Krag T; Dunø M; Hauerslev S; Vissing J
Brain; 2006 Dec; 129(Pt 12):3402-12. PubMed ID: 16815877
[TBL] [Abstract][Full Text] [Related]
33. AZT myopathy and HIV-1 polymyositis: one disease or two?
Walsh K; Kaye K; Demaerschalk B; Stewart S; Crukley J; Hammond R
Can J Neurol Sci; 2002 Nov; 29(4):390-3. PubMed ID: 12463497
[TBL] [Abstract][Full Text] [Related]
34. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy.
Bronner IM; Hoogendijk JE; Wintzen AR; van der Meulen MF; Linssen WH; Wokke JH; de Visser M
J Neurol; 2003 Apr; 250(4):480-5. PubMed ID: 12700915
[TBL] [Abstract][Full Text] [Related]
35. Cytochrome c oxidase deficiency in zidovudine myopathy affects perifascicular muscle fibres and arterial smooth muscle cells.
Chariot P; Le Maguet F; Authier FJ; Labes D; Poron F; Gherardi R
Neuropathol Appl Neurobiol; 1995 Dec; 21(6):540-7. PubMed ID: 8745244
[TBL] [Abstract][Full Text] [Related]
36. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
[TBL] [Abstract][Full Text] [Related]
37. [Muscular involvement in the course of AIDS. Anatomo-clinical study of 17 cases].
Butori C; Desnuelle C; Hofman P; Paquis V; Durant J; Carles M; Pesce A; Michiels JF
Ann Pathol; 1995; 15(6):424-30. PubMed ID: 8720838
[TBL] [Abstract][Full Text] [Related]
38. Myopathy in human immunodeficiency virus-infected children receiving long-term zidovudine therapy.
Walter EB; Drucker RP; McKinney RE; Wilfert CM
J Pediatr; 1991 Jul; 119(1 Pt 1):152-5. PubMed ID: 1906098
[No Abstract] [Full Text] [Related]
39. Exacerbation of HIV-associated myopathy by zidovudine.
Berger JR; Shebert R; Gregorios JB
AIDS; 1991 Feb; 5(2):229-30. PubMed ID: 2031699
[No Abstract] [Full Text] [Related]
40. Myopathy in HIV infection: the role of zidovudine and the significance of tubuloreticular inclusions.
Lane RJ; McLean KA; Moss J; Woodrow DF
Neuropathol Appl Neurobiol; 1993 Oct; 19(5):406-13. PubMed ID: 8278024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
